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Abstract
The American College of Cardiology Foundation along with
key specialty and subspecialty societies, conducted an appro-
priate use review of common clinical presentations for stable
ischemic heart disease (SIHD) to consider use of stress testing
and anatomic diagnostic procedures. This document reﬂects
an updating of the prior Appropriate Use Criteria (AUC)
published for radionuclide imaging (RNI), stress echocardi-
ography (Echo), calcium scoring, coronary computed
tomography angiography (CCTA), stress cardiac magnetic
resonance (CMR), and invasive coronary angiography for
SIHD. This is in keeping with the commitment to revise and
reﬁne theAUCon a frequent basis. Amajor innovation in this
document is the rating of tests side by side for the same indi-
cation. The side-by-side rating removes any concerns about
differences in indicationor interpretation stemming fromprior
use of separate documents for each test. However, the ratings
were explicitly not competitive rankings due to the limited
availability of comparative evidence, patient variability, and
range of capabilities available in any given local setting.
The indications for this review are limited to the
detection and risk assessment of SIHD and were drawnfrom common applications or anticipated uses, as well as
from current clinical practice guidelines. Eighty clinical
scenarios were developed by a writing committee and
scored by a separate rating panel on a scale of 1 to 9, to
designate Appropriate, May Be Appropriate, or Rarely
Appropriate use following a modiﬁed Delphi process
following the recently updated AUC development
methodology.
The use of some modalities of testing in the initial eval-
uation of patients with symptoms representing ischemic
equivalents, newly diagnosed heart failure, arrhythmias, and
syncope was generally found to be Appropriate or May Be
Appropriate, except in cases where low pre-test probability
or low risk limited the beneﬁt of most testing except
exercise electrocardiogram (ECG). Testing for the evalua-
tion of new or worsening symptoms following a prior test or
procedure was found to be Appropriate. In addition, testing
was found to be Appropriate or May Be Appropriate for
patients within 90 days of an abnormal or uncertain prior
result. Pre-operative testing was rated Appropriate or May
Be Appropriate only for patients who had poor functional
capacity and were undergoing vascular or intermediate risk
surgery with 1 or more clinical risk factors or an organ
transplant. The exercise ECG was suggested as an Appro-
priate test for cardiac rehabilitation clearance or for exercise
prescription purposes.
Testing in asymptomatic patients was generally found to
be Rarely Appropriate, except for calcium scoring and
exercise testing in intermediate and high-risk individuals
and either stress or anatomic imaging in higher-risk indi-
viduals, which were all rated as May Be Appropriate. All
modalities of follow-up testing after a prior test or percuta-
neous coronary intervention (PCI) within 2 years and within
5 years after coronary artery bypass graft (CABG) in the
absence of new symptoms were rated Rarely Appropriate.
Pre-operative testing for patients with good functional
capacity, prior normal testing within 1 year, or prior to low-
risk surgery also were found to be Rarely Appropriate.
Imaging for an exercise prescription or prior to the initiation
of cardiac rehabilitation was Rarely Appropriate except for
cardiac rehabilitation clearance for heart failure patients.Preface
In an effort to respond to the need for the rational use of
imaging services in the delivery of high-quality care, the
American College of Cardiology Foundation (ACCF) has
undertaken a process to determine the appropriate use of
cardiovascular imaging for selected patient indications.
Appropriate Use Criteria (AUC) publications reﬂect an
ongoing effort by the ACCF to critically and systematically
create, review, and categorize clinical situations where tests
and procedures are utilized by physicians caring for patients
with cardiovascular diseases. The process is based on
current understanding of the technical capabilities of the
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383procedures examined, evidence base, and clinical experi-
ence. Although not intended to be entirely comprehensive,
the indications are meant to identify common scenarios
encompassing the majority of contemporary practice.
Given the breadth of information they convey, the indi-
cations do not directly correspond to the Ninth Revision of
the International Classiﬁcation of Diseases system as these
codes do not include clinical information, such as symptom
status.
The ACCF believes that careful blending of a broad
range of clinical experiences and available evidence-based
information will help guide a more efﬁcient and equi-
table allocation of health care resources in cardiovascular
imaging. The ultimate objective of AUC is to improve
patient care and health outcomes in a cost-effective manner
but is not intended to ignore ambiguity and nuance
intrinsic to clinical decision making. Local parameters,
such as the availability or quality of equipment or personnel
may inﬂuence the selection of appropriate imaging proce-
dures. AUC, thus, should not be considered substitutes for
sound clinical judgment and practice experience.
We are grateful to the rating panel, a professional group
with a wide range of skills and insights, for their thoughtful
and thorough deliberation of the merits of cardiac testing
for stable ischemic heart disease (SIHD). In addition to
our thanks to the rating panel for their dedicated work and
review; we would like to offer special thanks to the many
individuals who provided a careful review of the draft
indications; to Jenissa Haidari and Joseph Allen, who
continually drove the process forward; and to the entire
Task Force for their dedication, insight, and leadership.
Michael J. Wolk, MD, MACC
Past Chair, Appropriate Use Criteria Task Force
Ralph G. Brindis, MD, MPH, FACC, FSCAI
Moderator, Multimodality Appropriate Use Criteria for the
Detection and Risk Assessment of Stable Ischemic Heart
Disease Rating Panel1. Introduction
Since the introduction of AUC in 2005, the ACCF has
produced a number of documents that synthesize evidence
for a speciﬁc cardiovascular procedure into appropriateness
standards. The AUC were developed to support utilization
of high-quality patterns of procedure use (i.e., appropriate
use) while informing efforts to reduce resource use when
beneﬁts to patients are unlikely (1–3).
The range of tools used to evaluate cardiovascular
disease has expanded over the past decade, especially in the
ﬁeld of noninvasive imaging. The purpose of this docu-
ment is to delineate the appropriate use of various invasive
and noninvasive testing modalities for the diagnosis and/or
evaluation of SIHD across common patient presentations
(indications), including:1. Patients with signs and/or symptoms and/or various
levels of risk for coronary disease (Section 1);
2. Patients with prior test results or coronary revascu-
larization for follow-up evaluation (Section 2);
3. Patients scheduled for noncardiac surgery
(Section 3);
4. Patients with an exercise prescription or referral to
cardiac rehabilitation (Section 4).2. Methods
The methods for development of AUC have evolved over
time and were recently updated (2,3). A general overview
of the methods is described in the following text.
The document is organized around the diagnostic and
prognostic capabilities of anatomic and stress testing proce-
dures to guide therapeutic choices for common clinical
scenarios in the evaluation and follow-up of stable ischemic
heart disease (SIHD).This document considers symptomatic
and asymptomatic presentations for patientswith andwithout
a prior history of SIHD, coronary testing, or cardiac proce-
dures. This approach more closely approximates the testing
options available during an episode of care and therefore
potentially offers a single AUC reference for cardiovascular
specialists and referring physicians. Rather than attempting to
determine a single best test for each indication, the goal of this
document was to determine which testing modalities, if any,
may or may not be reasonable for a speciﬁc indication.Indication Development
The indications have been developed by a diverse writing
committee composed of experts in both invasive and
noninvasive diagnostic cardiac testing as well as general
cardiology. Within each main indication category, a stan-
dardized approach has been used to capture the majority of
clinical scenarios for which patients are referred for testing.
Still, the writing committee recognizes that patient
presentations vary widely and not all clinical factors are
fully captured by these standardized scenarios. Indications
were modiﬁed based on feedback from independent
reviewers composed of both cardiovascular experts as well
as those in general practice or in related specialty ﬁelds.Rating Process and Scoring
Once the indications were ﬁnalized, a rating panel scored
the indications independently. To ensure a diversity of
expertise in the scoring process, the rating panel deliber-
ately comprised individuals with a diversity of expertise,
among which <50% regularly performed the particular
procedures under evaluation. Wherever possible, indica-
tions have been mapped to relevant ACCF/AHA and
subspecialty clinical practice guidelines and key publica-
tions/references (Online Appendix 1).
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384In scoring these criteria, the rating panel was asked to
assess whether the use of the test for each indication is
Appropriate, May Be Appropriate, or Rarely Appropriate,
andwas provided the following deﬁnition of appropriate use:
An appropriate imaging study is one in which the
expected incremental information, combined with clinical
judgment, exceeds the expected negative consequences* by
a sufﬁciently wide margin for a speciﬁc indication that the
procedure is generally considered acceptable care and
a reasonable approach for the indication.
The rating panel scored each indication as follows:
Median Score 7 to 9: Appropriate Care
An appropriate option for management of patients in
this population because of beneﬁts generally outweighing
risks; effective option for individual care plans although not
always necessary depending on physician judgment and
patient-speciﬁc preferences (i.e., procedure is generally
acceptable and is generally reasonable for the indication).
Median Score 4 to 6: May Be Appropriate Care
At times an appropriate option for management of
patients in this population due to variable evidence or
agreement regarding the beneﬁt/risk ratio, potential beneﬁt
based on practice experience in the absence of evidence,
and/or variability in the population; effectiveness for
individual care must be determined by a patient’s physician
in consultation with the patient, based on additional
clinical variables and judgment along with patient prefer-
ences (i.e., procedure may be acceptable and may be
reasonable for the indication).
Median Score 1 to 3: Rarely Appropriate Care
Rarely an appropriate option for management of patients
in this population due to the lack of a clear beneﬁt/risk
advantage; rarely an effective option for individual care
plans; exceptions should have documentation of the clinical
reasons for proceeding with this care option (i.e., procedure
is not generally acceptable and is not generally reasonable
for the indication).
After independent rating, the panel was convened for
a face-to-face meeting for discussion of each indication. At
this meeting, panel members were provided with their
scores and a blinded summary of their peers’ scores. Panel
members had the opportunity to suggest modiﬁcations to
the indications based on the discussion. After the meeting,
panel members were then asked to independently provide
their ﬁnal scores for each indication.
The level of agreement among panelists, as deﬁned by
RAND (4), was analyzed based on the BIOMED Con-
certedAction onAppropriateness rule for a panel of 14 to 16.*Negative consequences include the risks of the procedure radiation or contrast
exposure and the downstream impact of poor test performance such as delay in
diagnosis (false negatives) or inappropriate diagnosis (false positives).As such, agreement was deﬁned as an indication where 4 or
fewer panelists’ ratings fell outside the 3-point region con-
taining themedian score.Disagreementwas deﬁned aswhere
at least 5 panelists’ ratings fell in both the appropriate and the
inappropriate categories. Any indication having disagree-
ment was categorized as uncertain, regardless of the ﬁnal
median score. Indications that meet neither deﬁnition for
agreement or disagreement are in a third, unlabeled, category.
3. Assumptions
To limit inconsistencies in interpretation, these speciﬁc
assumptions should be considered when interpreting the
ratings.
General Assumptions/Considerations
1. Each test is performed in compliance with published
criteria for quality cardiac diagnostic testing as
provided by national laboratory accreditation “stan-
dards” (i.e., Intersocietal Accreditation Commission,
American College of Radiology) and societal “quality”
guidelines documents, and interpreted by physicians
who are qualiﬁed to do so.
Stress echocardiography (echo) (5–7)
Radionuclide myocardial perfusion imaging
(MPI) (8–11)
Cardiac magnetic resonance (CMR) (12–15)
Coronary computed tomography angiography
(CCTA) (16–19)
Invasive coronary angiography (cath) (20,21)
Radiation (22–24)
Although geographic differences may exist in the avail-
ability or quality of the different modalities, raters were
asked to make determinations based on published diag-
nostic and prognostic performance of the testing
modalities. In other words, the rater should assume that
each modality is locally available and performed on
appropriate equipment, and is interpreted by individuals
with acceptable training and expertise,when scoring each
indication.
2. The clinical status of the patient should be assumed to
be valid as stated in the indication (e.g., a thorough
history and physical exam have occurred such that an
asymptomatic patient is truly asymptomatic for the
condition in question).
3. Evaluation of all indications is taking place under
nonurgent circumstances.
4. All patients are receiving optimal standard care,
including guideline-based risk factor modiﬁcation for
primary or secondary prevention of ischemic heart
disease unless speciﬁcally noted.
5. In the event of an ambiguous angiogram, either
intravascular ultrasound or fractional ﬂow reserve may
be performed as needed.
Figure 1. Hierarchy of Potential Test Ordering Based on Clinical Presentation
For those patients who may be classiﬁed into more than 1 of the clinical indication tables and/or algorithms, this ﬂowchart places clinical conditions into a hierarchy to aid in
assessing appropriateness. Patients sent for testing for purposes of pre-operative cardiac assessment who are rated Rarely Appropriate for testing based on surgery alone may be
considered for testing for other reasons (e.g., symptomatic). CABG ¼ coronary artery bypass graft; CAD ¼ coronary artery disease; CV ¼ cardiovascular; PCI ¼ percutaneous
coronary intervention.
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3856. If the patient’s characteristics are captured under more
than 1 indication, the patient should be categorized
according to the hierarchy provided in Figure 1.
7. Indications that describe routine or surveillance
imaging imply that the test is being considered, not
because of any change in clinical circumstances or any
need to consider a change in therapy, but rather, solely
because a period of time has elapsed.
8. For certain indications, emphasis has been placed
upon the patient’s ability to exercise and achieve 85%
of their age-predicted maximal heart rate (220 
age). When the patient’s ability to exercise is not
explicitly stated, it should be assumed that the
patient can exercise to a symptomatic endpoint
or 85% of their age-predicted maximal heart rate.
Similarly, it should be assumed that the electrocar-
diogram (ECG) is interpretable unless otherwise
stated.
9. The mode of stress testing is assumed to be exercise
(e.g., treadmill, bicycle) for patients able to exercise
for the modalities for which some form of “stress” is
required. For patients unable to exercise, it is
assumed that pharmacological stress may be per-
formed using the appropriate agent and/or with or
without low level exercise. For CMR, it is assumed
that vasodilator stress perfusion is the technique
used.10. Selection for and monitoring of contrast use is
assumed to be in accord with published standards
documents, when available (14,24).Multimodality-Speciﬁc Assumptions/
Considerations
Comparative Rating
11. Testing modalities are rated for their level of appropri-
ateness speciﬁc to clinical scenarios, rather than a forced,
rank order comparison against other testing modalities.
The goal of this document is to identify any and all tests
that are considered reasonable for a given clinical indi-
cation. Determination of the range of modalities that
may or may not be reasonable for speciﬁc indications is
the goal of this document, rather than determining
a single best test for each indication or a rank order. As
such, more than 1 test type or even all tests may be
considered “Appropriate,” “May Be Appropriate,” or
“Rarely Appropriate” for any given clinical indication.
12. If more than 1 modality falls into the same appropriate
use category, it is assumed that physician judgment
and available local expertise will be used to determine
the correct test for an individual patient.
13. As with all previously published clinical policies,
deviations by the rating panel from prior published
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mentation knowledge that justiﬁes such evolution.
However, the reader is advised to pay careful attention to
the wording of an indication in the present document
when making comparisons to prior publications.
14. Indication ratings containedherein supersede the ratings
of similar indications contained in previous AUC
documents.
Risk/Beneﬁt
15. Overall, the patient presentation as described by each
indication was used in the risk/beneﬁt calculation.
Each modality considered in this document has
inherent risks that may include, but are not limited to:
radiation exposure, contrast sensitivity, other bodily
injury, and interpretation error. For any test, there may
be certain patient populations that are more suscep-
tible to known risks of a test type that are not
speciﬁcally captured in the indications, but that
deserve consideration when rating. Such risks should
be viewed “on balance” and not used as justiﬁcation to
systematically reduce the level of appropriateness of
a particular test compared with other tests (e.g., tests
that impart ionizing radiation should not necessarily
receive a lower score than tests that do not). Thus,
a given modality should be weighed speciﬁcally in the
context of the clinical scenario, with the potential risks
considered relative to the potential beneﬁt gained.
Contraindications
16. Unless explicitly stated, it should be assumed that
patients presenting for a speciﬁc clinical indication are
potential candidates for all of the test types to be rated,
and do not present with strong contraindications that
preclude them from being tested (e.g., renal dysfunc-
tion, presence of an implanted device, etc.).
Radiation Safety
17. Speciﬁc evidence relating to an increased cancer risk due
to radiation exposure following the commonly applied
cardiovascular (CV) imaging modalities has not been
systematically reported, although many experts in the
ﬁeld of radiation biology and epidemiology support
a linear no-threshold hypothesis whereby any exposure
is related to a long-term projected risk of cancer (22,23).
18. The following radiation safety concepts are being
applied for each scenario (25):
A. Clinical beneﬁt should be As High As Reasonably
Achievable (AHARA). AHARA should be used for
the identiﬁcation of patients for whom the use of CV
imaging results in higher overall clinical beneﬁt.
Adherence to AHARA embraces the guiding prin-
ciple that testing should be geared toward at-risk
cohorts that are most likely to experience a net
beneﬁt from testing, as deﬁnedbya clinical indication.B. Radiation exposure should be As Low As Reason-
ably Achievable (ALARA). ALARA should be
used to guide both test choice and test protocols
emphasizing dose-reduction techniques while
preserving diagnostic image quality. Implicit in the
principle of ALARA is the limitation of radiation
exposure from CV imaging within vulnerable pop-
ulations such as younger patients, in whom the
projected cancer risk arising from radiation
exposure may be higher than for older patients.19. For each clinical scenario, tests that impart ionizing
radiation will be performed by labs that have adopted
contemporary dose-reduction techniques (24). Based
on the available evidence, optimized dose-reduction
strategies may be employed in large segments of the
adult population and should be widely utilized.
Cost/Value
20. The differential costs between modalities have nar-
rowed in recent years and vary depending on payer and
site of service, thus making the relevance of baseline
cost to test selection less germane (Online Appendix 2).
As such, expectations of lower procedural costs should
not be reﬂexively favored.
21. Clinical beneﬁts should always be considered ﬁrst, and
costs should be considered in relationship to these
beneﬁts in order to better convey net value. For
example, a procedure with moderate clinical efﬁcacy for
a given AUC indication should not be scored as more
appropriate than a procedure with high clinical efﬁcacy
solely due to its lower cost. When available, scientiﬁc
evidence exists to support clinical beneﬁt, cost efﬁ-
ciency, and cost effectiveness should be considered for
any indication. In addition to net health beneﬁts versus
risks, value may be informed by multiple measures of
potential economic impact, such as:
 Induced downstream or layered testing rates (e.g.,
angiography);
 Comparative cost savings or minimization for
diagnosis or near-term follow-up;
 Cost to reduce adverse outcomes (e.g., cost per
hospitalization averted);
 Cost per life-year gained;
 For cardiac tests, patterns of downstream costs or
potential cost savings for any given indication–
modality pairing should be considered implicitly.Evidence Review
Availability of Evidence
22. Whenever possible, clinical indications were rated in
relation to available data derived from randomized
trials and observational registries. When these data do
not exist, other published scientiﬁc evidence was
considered. For many indications, a simple review of
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sponsorship, and questions answered was insufﬁcient
to determine accuracy.
Time Biases in Available Data
23. Newer technologies should not be considered necessarily
more or less appropriate compared with older technolo-
gies. Apparent differences in diagnostic accuracy and risk
stratiﬁcation between older and newer techniques may
not be “real,” especially when not directly compared and
when historical data are utilized. As treatment paradigms
evolve, with diagnosis often occurring at earlier stages of
disease, the comparison of diagnostic modalities, often
used at different stages of the disease process, poses
unique challenges. Furthermore, as treatments evolve and
result in more effective risk reduction, detecting mean-
ingful outcome differences is more difﬁcult for newer
technologies or in contemporary comparative analyses.
Conversely, older literature supporting a given indication
for an established modality should not be disregarded or
perceived as irrelevant to today’s clinical testing practices.
In addition, older studies may fail to reﬂect technological
advances in a speciﬁc modality or the application of
a particular method to a reﬁned patient-reﬁned group.4. Deﬁnitions
Deﬁnitions of terms used throughout the indication set are
listed here.Deﬁnitions for All Sections
Symptomatic (includes potentially ischemic equivalents
as relevant): Chest Pain Syndrome or Anginal Equivalent
Patients may present with any constellation of clinical ﬁnd-
ings that the physician feels is consistent with coronary artery
disease (CAD). Examples of such ﬁndings include, but are
not limited to, chest pain, chest tightness, chest burning,
epigastric pain, shoulder pain, jaw pain, or other symptoms/
ﬁndings suggestive ofCAD.Non-chest pain symptoms (e.g.,
dyspnea or reduced/worsening effort tolerance) or signs (e.g.,
new electrocardiographic abnormalities) that are thought to
be consistent with CAD may also be considered to be an
ischemic equivalent. Symptomatic patients described in the
tables with certain pre-test probabilities are assumed to
present onlywith the relevant symptomatology (e.g., lowpre-
test probability patients may present with atypical or non-
anginal chest pain, but not typical chest pain or tightness).
Indication
A set of patient-speciﬁc conditions deﬁnes an indication.
The term clinical indication does not necessarily mean that
any test is warranted. In other words, for someclinical indications, all modalities may be rated as Rarely
Appropriate.
Unable to Exercise
Patient inability to exercise is assumed to be due to non-
cardiovascular issues such as arthritis and not cardiovascular
issues that would inherently increase a patient’s risk.
Deﬁnitions for Section 1
ECG: Uninterpretable
This refers to ECGs with resting abnormalities such as
ST-segment depression (0.10 mV), complete left bundle
branch block, pre-excitation (Wolff-Parkinson-White
syndrome), digoxin use, or ventricular paced rhythm that
would make the exercise ECG difﬁcult to interpret.
Deﬁnitions for Section 1: Table 1.1
Pre-Test Probability of CAD: Symptomatic
(Ischemic Equivalent) Patients
When symptoms are present, and there is sufﬁcient
suspicion of heart disease to warrant cardiac evaluation, the
clinician should make a probability estimate of the likeli-
hood of CAD prior to selecting testing. There are
a number of validated risk assessment models (26,27)
available that can be used to calculate this probability.
Clinicians should be familiar with those algorithms that
pertain to the populations they encounter most often. In
scoring the indications, the following probabilities, as
calculated from any of the various available validated
algorithms, should be applied.
 Low pre-test probability: <10% pre-test probability
of CAD;
 Intermediate pre-test probability: Between 10%
and 90% pre-test probability of CAD;
 High pre-test probability: >90% pre-test proba-
bility of CAD.
The method recommended by the ACCF/AHA
Guidelines for Stable Ischemic Heart Disease (28) is
provided as 1 example of a method used to calculate pre-test
probability and is a modiﬁcation of a previously published
literature review (29). Please refer to Table A and the deﬁ-
nition of angina characteristics. It is important to note that
other factors or ECG ﬁndings (e.g., prior infarction) can
affect pre-test probability, although these factors are not
accounted for in Table A. Similarly, although not incorpo-
rated into the algorithm, other CAD risk factors may also
affect pre-test likelihood of CAD. Detailed nomograms are
available that incorporate the effects of a history of prior
infarction, ECG Q waves, and ST- and T-wave changes,
diabetes, and other cardiac risk factors (30). Patients with
multiple established coronary risk factors not accounted for
inTableA are likely not to have<10% likelihood of coronary
artery disease and may require reclassiﬁcation.
Table A. Diamond and Forrester Pre-Test Probability of
Coronary Artery Disease by Age, Sex, and Symptoms*
Age
(years) Sex
Typical/Deﬁnite
Angina Pectoris
Atypical/Probable
Angina Pectoris
Nonanginal
Chest Pain
39 Men Intermediate Intermediate Low
Women Intermediate Very low Very low
40–49 Men High Intermediate Intermediate
Women Intermediate Low Very low
50–59 Men High Intermediate Intermediate
Women Intermediate Intermediate Low
60 Men High Intermediate Intermediate
Women High Intermediate Intermediate
High: >90% pre-test probability. Intermediate: between 10% and 90% pre-test probability. Low:
between 5% and 10% pre-test probability. Very low:<5% pre-test probability. *Modiﬁed from the
ACC/AHA 2002 Guideline Update for Exercise Testing (30a).
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 Typical Angina (Deﬁnite): Deﬁned as 1) substernal
chest pain or discomfort that is 2) provoked by
exertion or emotional stress and 3) relieved by rest
and/or nitroglycerin (31).Figure 2. Stepwise Approach to Perioperative Cardiac Assessment
Cardiac evaluation and care algorithm for noncardiac surgery based on active clinical condit
age. ACC ¼ American College of Cardiology; AHA ¼ American Heart Association; HR ¼ hear
et al. (38). Atypical Angina (Probable): Chest pain or
discomfort that lacks one of the characteristics of
deﬁnite or typical angina.
 Nonanginal Chest Pain: Chest pain or discomfort
that meets one or none of the typical angina
characteristics.
Deﬁnitions for Section 1: Table 1.2
and Section 2: Table 2.2
Global CAD Risk
It is assumed that clinicians will use current standard
methods of global risk assessment such as those presented
in the National Heart, Lung, and Blood Institute report on
Detection, Evaluation, and Treatment of High Blood
Cholesterol in Adults (Adult Treatment Panel III [ATP
III]) (32), PROCAM (33), or similar national guidelines.
 When applying a global risk score for asymptomatic
patients, risk is deﬁned as the probability of experi-
encing a CAD event over a given time period. The
ATP III report speciﬁes CAD event risk over theions, known cardiovascular disease, or cardiac risk factors for patients 50 years of
t rate; LOE ¼ level of evidence; MET ¼ metabolic equivalent. Modiﬁed from Fleisher
Table B. Active Cardiac Conditions for Which the Patient
Should Undergo Evaluation and Treatment Before Non-
Emergent Noncardiac Surgery (Class I, Level of Evidence: B)
Condition Examples
Unstable coronary syndromes Unstable or severe angina*
(CCS class III or IV)y
Recent MIz
Decompensated HF
(NYHA functional class IV;
worsening or new-onset HF)
Signiﬁcant arrhythmias High-grade atrioventricular block
Mobitz II atrioventricular block
Third-degree atrioventricular heart block
Symptomatic ventricular arrhythmias
Supraventricular arrhythmias (including
atrial ﬁbrillation) with uncontrolled
ventricular rate (HR >100 beats/min
at rest)
Symptomatic bradycardia
Newly recognized ventricular
tachycardia
Severe valvular disease Severe aortic stenosis (mean pressure
gradient >40 mm Hg, aortic valve
area <1.0 cm2, or symptomatic)
Symptomatic mitral stenosis
(progressive dyspnea on exertion,
exertional presyncope, or HF)
*According to Campeau (39); ymay include “stable” angina in patients who are unusually
sedentary; zthe American College of Cardiology National Database Library deﬁnes recent MI as
>7 days but 1 month (within 30 days). Reprinted from Fleisher et al. (38).
CCS¼ Canadian Cardiovascular Society; HF ¼ heart failure; HR ¼ heart rate; MI ¼myocardial
infarction; NYHA ¼ New York Heart Association.
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CAD risk refers to 10-year risk for myocardial
infarction or CAD death. However, acknowledging
that global risk scores may be miscalibrated in certain
populations (e.g., women, younger men), clinical
judgment may be used to document an exception to
the AUC. Moreover, important clinical risk factors,
such as family history of premature CAD, though
not included in global risk scoring, also may be
inﬂuential considerations in clinical judgment.
 Low global CAD risk
Deﬁned by an age-speciﬁc risk level that is below
average. In general, low risk will correlate with a
10-year absolute CAD risk <10%. However, in
women and younger men, low risk may correlate
with 10-year absolute CAD risk <6%.
 Intermediate global CAD risk
Intermediate risk is deﬁned as a 10-year CAD risk
from 10% to 20%. Among women and younger men,
an expanded intermediate-risk range of 6% to 20%
may be appropriate.
 High global CAD risk
High risk is deﬁned as a 10-year CAD risk of >20%.
CAD equivalents (e.g., diabetes mellitus, peripheral
arterial disease) can also deﬁne high risk.
Deﬁnitions for Section 1: Table 1.3
Heart Failure
Refer to stages B, C, and D heart failure as deﬁned by the
ACCF/AHA Guideline for the Management of Heart
Failure (33a).
Ventricular Tachycardia
A cardiac arrhythmia of 3 or more consecutive complexes
in duration that emanates from the ventricles at a rate of
>100 beats/min (cycle length <600 ms).
Sustained Ventricular Tachycardia
Ventricular tachycardia (VT) that is >30 seconds in
duration and/or requires termination due to hemodynamic
compromise in <30 seconds (34,35).
Nonsustained VT
Three or more consecutive beats of VT that self-terminate
in <30 seconds.
Frequent Premature Ventricular Contractions
More than 30 premature ventricular contractions (PVCs)
per hour (36).
Syncope
Transient loss of consciousness due to global cerebral
hypoperfusion characterized by rapid onset, short duration,
and spontaneous complete recovery (37), not light-
headedness or dizziness alone.Deﬁnitions for Section 2: All Tables
Nonobstructive Invasive Coronary Angiogram
Less than 50% luminal diameter narrowing, by visual
assessment, of an epicardial or left main stenosis measured
in the “worst view” angiographic projection.
Deﬁnitions for Section 3: All Tables
Evaluating Perioperative Risk for Noncardiac Surgery
Method for Determining Perioperative Risk
See Figure 2, “Stepwise Approach to Perioperative Cardiac
Assessment,” from the ACCF/AHA 2009 perioperative
guidelines (38). On the basis of the algorithm, once it is
determined that the patient does not require urgent
surgery, the clinician should determine the patient’s active
cardiac conditions (see Table B) and/or perioperative risk
predictors (see Table C). If any active cardiac conditions
and/or major risk predictors are present, Figure 2 suggests
a directed workup of the underlying condition, and post-
poning or canceling noncardiac surgery. Once perioper-
ative risk predictors are assessed based on the algorithm,
then the surgical risk and patient’s functional status should
be used to establish the need for noninvasive testing.
Table C. Perioperative Clinical Risk Factors*
 History of ischemic heart disease
 History of compensated or prior heart failure
 History of cerebrovascular disease
 Diabetes mellitus
 Renal insufﬁciency (creatinine >2.0)
*As deﬁned by the ACCF/AHA Guidelines on Perioperative Cardiovascular Evaluation and Care
For Noncardiac Surgery. Note that these are not standard coronary artery disease risk factors.
Reprinted from Fleisher et al. (38).
ACCF ¼ American College of Cardiology Foundation; AHA ¼ American Heart Association.
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AUC ¼ Appropriate Use Criteria
CABG ¼ coronary artery bypass graft
CAD ¼ coronary artery disease
CHD ¼ coronary heart disease
CMR ¼ cardiac magnetic resonance
CCTA ¼ coronary computed tomography angiography
ECG ¼ electrocardiogram
ECHO ¼ echocardiogram
METS ¼ metabolic equivalents
PCI ¼ percutaneous coronary intervention
PVC ¼ premature ventricular contraction
RNI ¼ radionuclide imaging
SIHD ¼ stable ischemic heart disease
VT ¼ ventricular tachycardiaTable 1.1. Symptomatic
Refer to pages 16 and 17 for relevant deﬁnitions, in particula
and risk factors relevant to each p
Indication Text
Exercise
ECG
Stres
RNI
1.  Low pre-test probability of CAD
 ECG interpretable AND able to exercise
A R
2.  Low pre-test probability of CAD
 ECG uninterpretable OR unable to exercise
A
3.  Intermediate pre-test probability of CAD
 ECG interpretable AND able to exercise
A A
4.  Intermediate pre-test probability of CAD
 ECG uninterpretable OR unable to exercise
A
5.  High pre-test probability of CAD
ECG interpretable AND able to exercise
M A
6.  High pre-test probability of CAD
 ECG uninterpretable OR unable to exercise
A
Appropriate Use Key: A ¼ Appropriate; M ¼ May Be Appropriate; R ¼ Rarely Appropriate.
A ¼ Appropriate; CAD ¼ coronary artery disease; CCTA ¼ coronary computed tomography angiograp
M ¼ May Be Appropriate; R ¼ Rarely Appropriate; RNI ¼ radionuclide imaging.6. Results of Ratings
The ﬁnal ratings for Multimodality AUC on the Detection
and Risk Assessment of SIHD are listed by indication in
Tables 1.1, 1.2, 1.3, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 3.1, 3.2,
3.3, 4.1, and 4.2. The ﬁnal score reﬂects the median
score of the 17 rating panel members and has been labeled
according to the categories of Appropriate (median 7 to 9),
May Be Appropriate (median 4 to 6), and Rarely Appro-
priate (median 1 to 3) (Online Appendix 3). Eighteen of
the 80 indications were considered Rarely Appropriate
across all modalities whereas the remainder were of mixed
appropriateness. The discussion section highlights further
general trends in the scoring related to speciﬁc patient
populations.7. Multimodality for the Detection and
Risk Assessment of Ischemic Heart Disease
Appropriate Use Criteria (by Indication)
Section 1. Detection of CAD/Risk Assessmentr Table A and text for age, sex, symptom presentation,
re-test probability category
s Stress
Echo
Stress
CMR
Calcium
Scoring CCTA
Invasive
Coronary
Angiography
M R R R R
A M R M R
A M R M R
A A R A M
A A R M A
A A R M A
hy; CMR ¼ cardiac magnetic resonance; ECG ¼ electrocardiogram; Echo ¼ echocardiography;
Table 1.2. Asymptomatic (Without Symptoms or Ischemic Equivalent)
Refer to pages 17 and 18 for relevant deﬁnitions
Indication Text
Exercise
ECG
Stress
RNI
Stress
Echo Stress CMR
Calcium
Scoring CCTA
Invasive
Coronary
Angiography
7.  Low global CHD risk
 Regardless of ECG interpretability and
ability to exercise
R R R R R R R
8.  Intermediate global CHD risk
 ECG interpretable and able to exercise
M R R R M R R
9.  Intermediate global CHD risk
ECG uninterpretable OR unable to exercise
M M R M R R
10.  High global CAD Risk
 ECG interpretable and able to exercise
A M M M M M R
11.  High global CAD Risk
 ECG uninterpretable OR unable to exercise
M M M M M R
Appropriate Use Key: A ¼ Appropriate; M ¼ May Be Appropriate; R ¼ Rarely Appropriate.
A ¼ Appropriate; CAD ¼ coronary artery disease; CCTA ¼ coronary computed tomography angiography; CHD ¼ coronary heart disease; CMR ¼ cardiac magnetic resonance; ECG ¼ electrocardiogram;
Echo ¼ echocardiography; M ¼ May Be Appropriate; R ¼ Rarely Appropriate; RNI ¼ radionuclide imaging.
Table 1.3. Other Cardiovascular Conditions
Refer to pages 18 and 19 for relevant deﬁnitions
Indication Text
Exercise
ECG
Stress
RNI
Stress
Echo
Stress
CMR
Calcium
Scoring CCTA
Invasive
Coronary
Angiography
Newly Diagnosed Heart Failure (Resting LV Function Previously Assessed but No Prior CAD Evaluation)
12.  Newly diagnosed systolic heart failure M A A A R A A
13.  Newly diagnosed diastolic heart failure M A A A R M M
Evaluation of Arrhythmias
Without Ischemic Equivalent (No Prior Cardiac Evaluation)
14.  Sustained VT A A A A R M A
15.  Ventricular Fibrillation M A A A R M A
16.  Exercise induced VT or nonsustained VT A A A A R M A
17.  Frequent PVCs A A A M R M M
18.  Infrequent PVCs M M M R R R R
19.  New-onset atrial ﬁbrillation M M M R R R R
20.  Prior to initiation of anti-arrhythmia therapy
in high global CAD risk patients
A A A A R M R
Syncope Without Ischemic Equivalent
21.  Low global CAD Risk M M M R R R R
22.  Intermediate or High Global CAD Risk A A A M R M R
Appropriate Use Key: A ¼ Appropriate; M ¼ May Be Appropriate; R ¼ Rarely Appropriate.
A ¼ Appropriate; CAD ¼ coronary artery disease; CCTA ¼ coronary computed tomography angiography; CMR ¼ cardiac magnetic resonance; ECG ¼ electrocardiogram; Echo ¼ echocardiography;
LV ¼ left ventricular; M ¼ May Be Appropriate; PVC ¼ premature ventricular contraction; R ¼ Rarely Appropriate; RNI ¼ radionuclide imaging; VT ¼ ventricular tachycardia.
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392Section 2. Prior Testing or ProcedureTable 2.0. Sequential Testing (90 Days): Abnormal Prior Test/Study)
Indication Text
Exercise
ECG
Stress
RNI
Stress
Echo
Stress
CMR
Calcium
Scoring CCTA
Invasive
Coronary
Angiography
23.  Abnormal rest ECG ﬁndings (potentially ischemic
in nature such as LBBB, T-wave inversions)
 Low global CAD risk
A A M R M R
24.  Abnormal rest ECG ﬁndings (potentially ischemic
in nature such as LBBB, T-wave inversions)
 Intermediate to high global CAD risk
A A A R M M
25.  Abnormal prior exercise ECG test A A A R A A
26.  Abnormal prior stress imaging study (assumes
not repeat of same type of stress imaging)
R M M M R A A
27.  Obstructive CAD on prior CCTA study M A A A A
28.  Obstructive CAD on prior invasive
coronary angiography
M A A A R R
29.  Abnormal prior CCT calcium
(Agatston Score >100)
A A A M M R
Appropriate Use Key: A ¼ Appropriate; M ¼ May Be Appropriate; R ¼ Rarely Appropriate.
A ¼ Appropriate; CAD ¼ coronary artery disease; CCT ¼ coronary computed tomography; CCTA ¼ coronary computed tomography angiography; CMR ¼ cardiac magnetic resonance; ECG ¼ elec-
trocardiogram; Echo ¼ echocardiography; LBBB ¼ left bundle branch block; M ¼ May Be Appropriate; R ¼ Rarely Appropriate; RNI ¼ radionuclide imaging.
Section 2.1. Prior Testing Without Intervening Revascularization
(If Intervening Revascularization Since Most Recent Test, Refer to Section 2.2)Table 2.1. Sequential or Follow-Up Testing (90 Days): Uncertain Prior Results
Indication text
Exercise
ECG
Stress
RNI
Stress
Echo
Stress
CMR
Calcium
Scoring CCTA
Invasive
Coronary
Angiography
Equivocal, Borderline, or Discordant Prior Noninvasive Evaluation
Where Obstructive CAD Remains a Concern
30.  Prior exercise ECG test A A A R A M
31.  Prior stress imaging study (assumes not repeat of
same type of stress imaging)
R M M M R A A
32.  Prior CCTA M A A A A
Prior Coronary Angiography (Invasive or Noninvasive)
33.  Coronary stenosis or anatomic abnormality of unclear
signiﬁcance found on cardiac CCTA
M A A A A
34.  Coronary stenosis or anatomic abnormality of unclear
signiﬁcance on previous coronary angiography
M A A A R R
Appropriate Use Key: A ¼ Appropriate; M ¼ May Be Appropriate; R ¼ Rarely Appropriate.
A ¼ Appropriate; CCTA ¼ coronary computed tomography angiography; CMR ¼ cardiac magnetic resonance; ECG ¼ electrocardiogram; Echo ¼ echocardiography; M ¼ May Be Appropriate; R ¼ Rarely
Appropriate; RNI ¼ radionuclide imaging.
Table 2.2. Follow-Up Testing (>90 Days): Asymptomatic or Stable Symptoms
Indication Text
Exercise
ECG
Stress
RNI
Stress
Echo
Stress
CMR
Calcium
Scoring CCTA
Invasive
Coronary
Angiography
Abnormal Prior Exercise ECG Test
Asymptomatic or Stable Symptoms
35.  Last test <2 years ago R R R R R R R
36.  Last test 2 years ago M M M R R R R
Abnormal Prior Stress Imaging Study
Asymptomatic or Stable Symptoms
37.  Last study <2 years ago R R R R R R R
38.  Last study 2 years ago R M M M R R R
Obstructive CAD on Prior Coronary Angiography (Invasive or Noninvasive)
Asymptomatic (Without Ischemic Equivalent) or Stable Symptoms
39.  Last study <2 years ago R R R R R R R
40.  Last study 2 years ago M M M M R R R
Prior Coronary Calcium Agatston Score
Asymptomatic (Without Ischemic Equivalent) or Stable Symptoms
41.  Agatston score <100 R R R R R R R
42.  Low to intermediate global CAD risk
Agatston score between 100 and 400
M M M R R R R
43.  High global CAD risk
Agatston score between 100 and 400
M M M M R R R
44.  Agatston score >400 A M M M R R R
Normal Prior Exercise ECG Test
Asymptomatic (Without Ischemic Equivalent)
45.  Low global CAD risk R R R R R R R
46.  Intermediate to high global CAD risk
 Test <2 years ago
R R R R R R R
47.  Intermediate to high global CAD risk
 Test 2 years ago
M M M M R R R
Normal Prior Stress Imaging Study
OR Nonobstructive CAD on Angiogram (Invasive or Noninvasive)
Asymptomatic (Without Ischemic Equivalent)
48.  Low global CAD risk R R R R R R R
49.  Intermediate to high global CAD risk
 Study <2 years ago
R R R R R R R
50.  Intermediate to high global CAD risk
 Study 2 years ago
M M M M R R R
Normal Prior Exercise ECG Test
Stable Symptoms
51.  Low global CAD risk R R R R R R R
52.  Intermediate to high global CAD risk
 Test <2 years ago
R R R R R R R
53.  Intermediate to high global CAD risk
 Test 2 years ago
M M M M R R R
Normal Prior Stress Imaging Study
OR Nonobstructive CAD on Angiogram (Invasive or Noninvasive)
Stable Symptoms
54.  Low global CAD risk R R R R R R R
55.  Intermediate to high global CAD risk
 Study <2 years ago
R R R R R R R
56.  Intermediate to high global CAD risk
 Study 2 years ago
M M M M R R R
Appropriate Use Key: A ¼ Appropriate; M ¼ May Be Appropriate; R ¼ Rarely Appropriate.
A ¼ Appropriate; CAD ¼ coronary artery disease; CCTA ¼ coronary computed tomography angiography; CMR ¼ cardiac magnetic resonance; ECG ¼ electrocardiogram; Echo ¼ echocardiography;
M ¼ May Be Appropriate; R ¼ Rarely Appropriate; RNI ¼ radionuclide imaging.
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Table 2.3. Follow-Up Testing: New or Worsening Symptoms
Indication Text
Exercise
ECG
Stress
RNI
Stress
Echo
Stress
CMR
Calcium
Scoring CCTA
Invasive
Coronary
Angiography
57.  Normal exercise ECG test M A A A R A M
58.  Nonobstructive CAD on coronary angiography
(invasive or noninvasive) OR normal prior stress imaging study
M A A A R R M
59.  Abnormal exercise ECG test R A A A R A A
60.  Abnormal prior stress imaging study R M M M R A A
61.  Obstructive CAD on CCTA study M A A A R R A
62.  Obstructive CAD on invasive coronary angiography A A A M R R A
63.  Abnormal CCTA calcium (Agatston Score >100) A A A A R M A
Appropriate Use Key: A ¼ Appropriate; M ¼ May Be Appropriate; R ¼ Rarely Appropriate.
A ¼ Appropriate; CAD ¼ coronary artery disease; CCTA ¼ coronary computed tomography angiography; CMR ¼ cardiac magnetic resonance; ECG ¼ electrocardiogram; Echo ¼ echocardiography;
M ¼ May Be Appropriate; R ¼ Rarely Appropriate; RNI ¼ radionuclide imaging.
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394Section 2.2. Post-Revascularization (PCI or CABG)Table 2.4. Symptomatic (Ischemic Equivalent)
Indication Text
Exercise
ECG
Stress
RNI
Stress
Echo
Stress
CMR
Calcium
Scoring CCTA
Invasive
Coronary
Angiography
64.  Evaluation of ischemic equivalent M A A A R M A
A ¼ Appropriate; CCTA ¼ coronary computed tomography angiography; CMR ¼ cardiac magnetic resonance; ECG ¼ electrocardiogram; Echo ¼ echocardiography; M ¼ May Be Appropriate; R ¼ Rarely
Appropriate; RNI ¼ radionuclide imaging.Table 2.5. Asymptomatic (Without Ischemic Equivalent)
Indication Text
Exercise
ECG
Stress
RNI
Stress
Echo
Stress
CMR
Calcium
Scoring CCTA
Invasive
Coronary
Angiography
65.  Incomplete revascularization
 Additional revascularization feasible
M A A M R R R
66.  Prior left main coronary stent M M M M R M M
67.  <5 years after CABG R R R R R R R
68.  5 years after CABG M M M M R R R
69.  <2 years after PCI R R R R R R R
70.  2 years after PCI M M M M R R R
Appropriate Use Key: A ¼ Appropriate; M ¼ May Be Appropriate; R ¼ Rarely Appropriate.
A ¼ Appropriate; CABG ¼ coronary artery bypass graft; CCTA ¼ coronary computed tomography angiography; CMR ¼ cardiac magnetic resonance; ECG ¼ electrocardiogram; Echo ¼ echocardiography;
M ¼ May Be Appropriate; PCI ¼ percutaneous coronary intervention; R ¼ Rarely Appropriate; RNI ¼ radionuclide imaging.Section 3. Pre-Operative Evaluation for Noncardiac SurgeryTable 3.1. Moderate-to-Good Functional Capacity (4 METs) OR No Clinical Risk Factors
Refer to pages 12 and 13 for relevant deﬁnitions
Indication Text
Exercise
ECG
Stress
RNI
Stress
Echo
Stress
CMR
Calcium
Scoring CCTA
Invasive
Coronary
Angiography
71.  Any surgery R R R R R R R
Appropriate Use Key: A ¼ Appropriate; M ¼ May Be Appropriate; R ¼ Rarely Appropriate.
CCTA ¼ coronary computed tomography angiography; CMR ¼ cardiac magnetic resonance; ECG ¼ electrocardiogram; Echo ¼ echocardiography; R ¼ Rarely Appropriate; RNI ¼ radionuclide imaging.
Table 3.2. Asymptomatic AND < 1 Year Post Any of the Following: Normal CT or Invasive Angiogram,
Normal Stress Test for CAD, or Revascularization
Refer to pages 12 and 13 for relevant deﬁnitions
Indication Text
Exercise
ECG
Stress
RNI
Stress
Echo
Stress
CMR
Calcium
Scoring CCTA
Invasive
Coronary
Angiography
72.  Any surgery R R R R R R R
Appropriate Use Key: A ¼ Appropriate; M ¼ May Be Appropriate; R ¼ Rarely Appropriate.
CCTA ¼ coronary computed tomography angiography; CMR ¼ cardiac magnetic resonance; ECG ¼ electrocardiogram; Echo ¼ echocardiography; R ¼ Rarely Appropriate; RNI ¼ radionuclide imaging.
Table 3.3. Poor or Unknown Functional Capacity (<4 METs)
Refer to pages 12 and 13 for relevant deﬁnitions
Indication Text
Exercise
ECG
Stress
RNI
Stress
Echo
Stress
CMR
Calcium
Scoring CCTA
Invasive
Coronary
Angiography
73.  Low-risk surgery
 1 clinical risk factor
R R R R R R R
74.  Intermediate-risk surgery
 1 clinical risk factor
M M M M R R R
75.  Vascular surgery
 1 clinical risk factor
M A A M R R R
76.  Kidney transplant M A A M R R M
77.  Liver transplant M A A M R R M
Appropriate Use Key: A ¼ Appropriate; M ¼ May Be Appropriate; R ¼ Rarely Appropriate.
A ¼ Appropriate; CCTA ¼ coronary computed tomography angiography; CMR ¼ cardiac magnetic resonance; ECG ¼ electrocardiogram; Echo ¼ echocardiography; M ¼ May Be Appropriate; R ¼ Rarely
Appropriate; RNI ¼ radionuclide imaging.
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395Section 4. Determine Exercise Level Prior to Initiation of Exercise Prescription or Cardiac RehabilitationTable 4.1. Exercise Prescription
Indication Text
Exercise
ECG
Stress
RNI
Stress
Echo
Stress
CMR
Calcium
Scoring CCTA
Diagnostic
Coronary
Angiography
78.  No prior revascularization A R R R R R R
Appropriate Use Key: A ¼ Appropriate; M ¼ May Be Appropriate; R ¼ Rarely Appropriate.
A ¼ Appropriate; CAD ¼ coronary artery disease; CCTA ¼ coronary computed tomography angiography; CMR ¼ cardiac magnetic resonance; ECG ¼ electrocardiogram; Echo ¼ echocardiography;
R ¼ Rarely Appropriate; RNI ¼ radionuclide imaging.
Table 4.2. Prior to the Initiation of Cardiac Rehabilitation (As a Stand-Alone Indication): Able to Exercise
Indication Text
Exercise
ECG
Stress
RNI
Stress
Echo
Stress
CMR
Calcium
Scoring CCTA
Diagnostic
Coronary
Angiography
79.  Post revascularization (PCI or CABG) A R R R R R R
80.  Heart failure A M M M R R R
Appropriate Use Key: A ¼ Appropriate; M ¼ May Be Appropriate; R ¼ Rarely Appropriate.
A ¼ Appropriate; CABG ¼ coronary artery bypass graft; CCTA ¼ coronary computed tomography angiography; CMR ¼ cardiac magnetic resonance; ECG ¼ electrocardiogram; Echo ¼ echocardiography;
M ¼ May Be Appropriate; PCI ¼ percutaneous coronary intervention; R ¼ Rarely Appropriate; RNI ¼ radionuclide imaging.8. Discussion
The current paper represents considerable progress in the
development and evolution of the depth and extensiveness
of AUC documents on cardiovascular imaging procedures.
Initial AUC publications on indications for imaging in the
detection and risk assessment of SIHD were centered
around individual procedures. In the current document, we
present a synthesis of evidence and clinical experience for
all commonly employed noninvasive and invasive proce-
dures for diagnosis of CAD. Importantly, this is the ﬁrst
imaging AUC document that now integrates the rating of
variety of procedures ranging from the exercise ECG to the
diagnostic coronary angiogram, representing the array of
choices available to the medical community. In fact, the
exercise ECG is a commonly employed diagnostic proce-
dure that has not been represented in prior documents and
is now included in the current report. Given the paucity ofcomparative effectiveness data, the evidence base is insuf-
ﬁcient for cross-indication comparisons between modali-
ties and, thus, determining a single best procedure is not
possible. We believe that this evidence synthesis, repre-
senting decades of published reports, will foster a greater
knowledge base on the part of the referring physician to
promote optimized decision making within the diagnostic
evaluation of SIHD. This approach to current and future
AUC documents represents an effort to produce a single
AUC document on effective procedural choices for a given
clinical strategy rather than procedure speciﬁc AUC
documents.
Clinical Scenarios
The clinical scenarios represented in the document cover
a range of typical patient presentations, which represent
a range of appropriateness for each procedure. The use of
several modalities of testing in the initial evaluation of
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equivalents (i.e., newly diagnosed heart failure, arrhyth-
mias, or syncope) was generally found to be Appropriate or
May Be Appropriate, except in cases where low pre-test
probability or low risk limited the beneﬁt of most testing
except exercise ECG. Testing for the evaluation of new or
worsening symptoms following a prior test or procedure
was also found to be Appropriate. In addition, testing was
found to be Appropriate or May Be Appropriate for
patients within 90 days of an abnormal or uncertain prior
test result. Pre-operative testing was rated Appropriate or
May Be Appropriate only for patients who had poor
functional capacity and were undergoing intermediate or
vascular surgery with 1 or more clinical risk factors or prior
to an organ transplant. Exercise ECG was rated as an
Appropriate test for cardiac rehabilitation clearance or for
exercise prescription purposes.
By comparison to symptomatic patients, testing in
asymptomatic patients was generally found to be Rarely
Appropriate, except for calcium scoring and exercise
testing in intermediate- and high-risk individuals and
either stress or anatomic imaging in higher-risk individ-
uals, which were all rated as May Be Appropriate. All
modalities of follow-up testing after a prior test or PCI
within 2 years or within 5 years after CABG in the absence
of new symptoms were rated Rarely Appropriate. Pre-
operative testing for patients with good functional
capacity, prior normal testing within 1 year, or those
undergoing low-risk surgery also was found to be Rarely
Appropriate. Imaging for an exercise prescription or prior
to the initiation of cardiac rehabilitation was Rarely
Appropriate except for cardiac rehabilitation clearance for
heart failure patients.
Rating Changes From Prior Documents
This document supersedes prior AUC documents that
cover the same or similar clinical scenarios for individual
procedures (e.g., for the various stress imaging modalities
and anatomic procedures) (40–43).
Thirty-seven of the indications were rated differently in
the current document than they were rated in the prior
relevant documents (Online Appendix 4). Of these
divergences, 18 could be reasonably expected by virtue of
the fact that modalities were rated in tandem by 1 panel.
The current document incorporated slight wording
changes within the deﬁnitions and/or the indications
sections relative to previous documents in order to remove
inconsistencies. Other rating differences may be attributed
to the changing practice environment and evolution in
cumulative clinical experience with these procedures, and
maturation of the ﬁeld since the original documents’
publication. For instance, in this document, ratings for
stress CMR were more often in accord with the ratings for
stress RNI, stress echo, and exercise treadmill testing. This
may reﬂect the simultaneous rating of modalities and the
growing body of evidence supporting the utility andaccuracy of stress CMR (44–49). Of the remaining
19 divergent ratings, all but 1, in stress echo, were for
CCTA, coronary calcium scoring, and invasive coronary
angiography.
Six ratings were lower than previous documents, and all
were among asymptomatic patients. Despite supporting
evidence, these lower ratings for asymptomatic patients
may reﬂect concern, voiced by many physicians, that the
previous Appropriate Use ratings could have been mis-
interpreted as a recommendation to use these tests to
screen a broad swath of the U.S. population. Although the
general ratings are lower in the current document relative
to prior documents, both coronary artery calcium and
exercise ECG were rated as May Be Appropriate for
asymptomatic patients of intermediate global risk. As such,
1 of these tests can be an option for further evaluation of
potential SIHD in an individual patient when deemed
reasonable by the patient’s physician. For instance, prior
clinical practice guidelines have supported the role of
coronary artery calcium with a Class IIa, Level of Evidence
B recommendation for identifying at-risk individuals who
may qualify for risk detection and targeted prevention
efforts including altered medical therapeutic regiments
and/or lifestyle modiﬁcations.
For CCTA, there were 7 additional differences, 4 of
which recognized the value of CCTA in sequential or
follow-up testing. The improved rating of CCTA
following an abnormal stress imaging study may reﬂect the
evolution of the evidence base since prior ratings (50–52).
Notably, there were also a few indications where the ratings
of CCTA decreased, speciﬁcally for symptomatic patients
or in the pre-operative setting, ratings that are consistent
with the perioperative guidelines and recent SIHD
guidelines (28,38).
Another important difference from prior documents is
the May Be Appropriate rating for stress echo among
symptomatic patients with low pre-test probability and an
ability to exercise and an interpretable ECG, a presentation
also reviewed in the recent SIHD guideline (28). However,
stress echo was less strongly supported for this scenario
than exercise treadmill testing. In fact, although not
a rating choice, “no testing at all” may also be considered an
option in such low-risk cases since the low pre-test prob-
ability alone limits the value of a positive test in deter-
mining likelihood of disease and often could then
potentially lead to further testing. This is in keeping with
the concept that because a test was rated Appropriate or
May Be Appropriate, this does not indicate that a test must
be performed. If testing is considered, several studies and
an expert consensus statement have reviewed the utility of
exercise treadmill testing in this population, which is
largely composed of women <60 years old with atypical
and nonanginal presentations based on pre-test proba-
bility calculations (53,54). An ECG treadmill test can
serve as an effective initial test and signiﬁcantly reduce
the number of patients who proceed to further stress
JACC Vol. 63, No. 4, 2014 Wolk et al.
February 4, 2014:380–406 AUC for Multimodality of SIHD
397imaging or other testing (53). Despite the fact that
ST-segment depression and the ECG reading portion of
the test have been shown to be less reliable in women, the
ability to integrate multiple parameters (exercise capacity,
chronotropic response, heart rate response, blood pres-
sure response, and Duke Treadmill Score) from an
exercise ECG can provide physicians with the necessary
diagnostic accuracy, especially given the excellent nega-
tive predictive value of the test (55).
Interpretation, Assumptions,
and Future Directions
There are a number of important considerations in inter-
preting and applying the standards contained in this
document.
These new AUC are intended to provide guidance for
patients and clinicians when it comes tomaking a reasonable
testing choice amongst the available testing modalities for
SIHD detection or risk assessment. Although the various
modality ratings for each indication are presented together,
the ratings are not intended to be comparative or indicate
a “best test” for a given indication. Rather, each rating should
be interpreted as a summary of the available evidence sup-
plemented by expert opinion for an individual stress test or
anatomic procedure. For example, just because 2 stress
imaging modalities are rated as Appropriate and the third as
May Be Appropriate, it may still be reasonable to choose the
third modality for a particular patient due to his/her indi-
vidual characteristics. In performing the ratings, the tech-
nical panel was instructed not to compare modalities with
one another for any given indication. Rather, each test was to
be rated individually for each scenario based upon the quality
of the published evidence as well as the expert opinion of the
rating panel. In the absence of robust comparative effec-
tiveness evidence, a comparative rating approach would be
both premature and misleading. Thus, although these
ratings reﬂect the existing evidence base supplemented by
expert consensus, there is no doubt that more research is
needed to further identify, not only when to use any given
modality, but also when to favor one over another. Impor-
tantly, there are a number of ongoing large randomized trials
thatmay provide sufﬁcient evidence to allow for comparative
ratings in future documents (56,57).
The contributors also acknowledge that the division of
these scores into 3 rating categories of appropriate use is
often somewhat arbitrary and that the category designa-
tions should be viewed instead as a continuum. At the
same time, the AUC process is intended to be transparent
for users. Accordingly, the technical panel’s numerical
scores may be found online, Appendix 3. However, the
categorical ratings only, which are shown in the tables in
the preceding text, are intended for clinical use. The
contributors also recognize diversity in clinical opinion for
particular clinical scenarios. As such, the criteria can
inform procedure use, but physician judgment is required
for individual patient decisions. Furthermore, the clinicalscenario list is intended to be relatively comprehensive,
without being exhaustive. Accordingly, some patients
encountered in clinical practice may have extenuating
features such that they may not ﬁt exactly into any of the
clinical scenarios presented.
It is understood that procedures whose use is Appro-
priate or May Be Appropriate should be reimbursed when
applied in the suitable clinical scenario. In certain clinical
settings, procedures that are Rarely Appropriate may be
justiﬁable based on that patient’s particular clinical char-
acteristics. These exceptions should be clearly documented.
Additionally, it is assumed that the evaluation for SIHD
in these clinical scenarios occurs in a nonurgent setting.
Thus, despite the recent publication of 3 randomized
comparative effectiveness trials of the use of CCTA in the
emergency department evaluation of low risk but acute chest
pain (58–60), the use of CCTA for this speciﬁc clinical
scenario is not addressed in this document because the
intended focus is for the outpatient evaluation of SIHD (61).
As with prior AUC documents, we anticipate that the
interpretation and application of these criteria will yield
insights into patterns of care and will help to inform future
iterations of these criteria. The ratings in the present docu-
ment will be re-evaluated on a regular basis as themodalities,
the evidence base, and the clinical landscape evolve. In
addition, future documents will rate clinical scenarios
involving cardiac structure and function assessment.
9. Conclusions
In summary, this document presents for the ﬁrst time,
side-by-side ratings of the multiple tests that are available
to the clinician for the detection of SIHD or risk assess-
ment purposes in the setting of 80 common scenarios. The
document is not intended to foster or imply competition
amongst modalities. It is intended to provide a practical
guide to individual clinicians and patients when consid-
ering 1 of these procedures, based on any number of
important local and patient-speciﬁc variables, while
promoting optimal test utilization for the population at
large. Recognizing that many modalities are available for
clinical decision making, it is anticipated that compiling
these modalities into 1 document will help clarify, for
clinicians, patients, and payers, when certain procedures
are Appropriate, are May Be Appropriate, or are Rarely
Appropriate in patients with known or suspected SIHD.
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